Methods: Gender, age, smoking habit, comorbidity, localization of the tumor, T status, N status, histological type, and pathological stage of patients who had undergone resection of pulmonary carcinoid tumor between January 1, 2005 and December 31, 2016 were retrospectively reviewed.
Results: A total of 47 patients (18 male, 29 female; mean age 50.5 years; range, 23 to 74 years) consisting of 40 typical and 7 atypical carcinoid tumor cases were included in our study. Anatomical resection and systematic mediastinal lymph node dissection was performed on all patients. Pathological studies revealed lymphatic involvement in six patients (12.8%; 4 pN1 and 2 pN2). In the typical group (n=40), three patients were classified N1 (7.5%) and one patient N2 (2.5%). In the atypical group (n=7), one patient were classified N1 (14.3%) and one patient N2 (14.3%). Throughout the study, four patients with typical histology (10%) and two patients with atypical histology (28.6%) had nodal involvement. All six patients with nodal involvement underwent adjuvant radiotherapy. Atypical histology (p=0.005) and nodal involvement (p=0.008) were determined as negative prognostic factors in statistical analysis.
Conclusion: Systematic hilar and mediastinal nodal dissection play a crucial role in the surgical treatment of pulmonary carcinoid tumors.
Table 1: Variables regarding tumor histology
Operations included lobectomy in 38 (80.9%; sleeve lobectomy in 7), bilobectomy in seven (14.9%; sleeve bilobectomy in 1), and pneumonectomy in two patients (4.3%; sleeve tracheal pneumonectomy in 1) (Table 2). Non-anatomic resection was not performed in any of the patients. Eleven patients (23.4%) underwent resection using a minimally invasive video-assisted recent approach. All patients underwent complete tumor resection. Systematic lymph node dissection was performed as a standard approach in all patients. The mean number of resected lymph nodes was 13 (range, 6-18) per patient.
The majority of the patients (n=39) were in stage I (IA: 25, IB:14). Six were in stage II (IIA: 1, IIB:5), and two were in stage IIIA. Lymph node metastasis was detected in six cases (4 N1, 2 N2). Since radiotherapy may provide potential benefit, particularly in patients with lymph node-positive disease, the six patients with nodal involvement received adjuvant radiotherapy.
Postoperative mortality did not occur. Surgical complications included prolonged air leak (n=1), postoperative hemorrhage (n=1), and the morbidity rate was 4.3%. Pathological studies demonstrated lymphatic spread in six patients (12.8%; four pN1 and two pN2). In the typical group (n=40), three patients were classified N1 ( 7.5%) a nd o ne N 2 ( 2.5%). I n t he atypical group (n=7), one patient were classified N1 (14.3%) and one N2 (14.3%). Overall, four patients with typical histology (10%) and two patients with atypical histology (28.6%) had nodal involvement. A total of 41 patients were free of nodal involvement (87.2%). All patients (n=47) were followed up for a total of 2,444 months with a median observation time of 52 months (mean, 38 months; range, 11 to 146 months). Follow-up ended on October 2017. Five patients died (three from cancer and two from unrelated causes). All three of the patients who died from cancer were atypical carcinoid. The overall five-year survival rate was 88.2% and the mean survival time was 124.4 months (95% confidence interval, 107.4 to 141.3). Five-year survival was 94.4% in typical tumors (n=40), and 55.6% in atypical tumors (n=7; p=0.005) (Figure 1). According to N0 status (n=41), five-year survival was 90.5%, and N+ status (n=6), 80.0% (p=0.008) (Figure 2). Atypical histology and nodal invasion were found to be significant prognostic factors (Table 3). Tumor location (central versus peripheric), and stage did not seem to statistically affect survival (Figure 3 and 4). Five-year survival was 73.5% in male (n=21) and 91.6% in female patients (n=26; p=0.433). In patients under and over 50 years of age, five-year survival was 100% and 81.2%, respectively (p=0.474). In terms of smoking history, overall five-year survival was 93.3% in smokers and 86.7% in non-smokers (p=0.726).
Figure 1: Prognostic influence of tumor histology. Univariable analysis (Kaplan-Meier) (p=0.005).
Figure 2: Prognostic influence of nodal invasion. Univariable analysis (Kaplan-Meier) (p=0.008).
Table 3: Univariate analysis of prognostic factors for survival
Figure 3: Prognostic influence of tumor location. Univariable analysis (Kaplan-Meier) (p=0.717).
Some studies emphasize a relationship between tobacco use and atypical carcinoids, but whether or not carcinoid tumors are associated with smoking is still a matter of debate.[6] Thirty three percent of patients in our study with typical and 57% with atypical tumors were smokers, and we did not observe a statistically significant difference in terms of survival (p=0.726).
At present, some authors believe that intraoperative lymph node dissection may not be essential, especially in the surgical treatment of typical carcinoid tumors.[7] Wurtz et al.[8] reported that systematic nodal dissection showed a high frequency of unpredictable lymphatic spread, mainly in the typical carcinoid group. A growing number of reports are emphasizing the potentially curative effect of systematic nodal dissection even in typical carcinoid tumors.[8-10] We also believe that surgical resection of carcinoid tumors and complete systematic lymph node dissection is necessary to determine possible lymph node metastasis. In our study, all patients underwent systematic mediastinal lymph node dissection. At least three lymph nodes from the 4th, 7th, 8th, 9th, and 10th zones in the right hemithorax and the 5th, 6th, 7th, 8th, 9th, and 10th zones in the left hemithorax were dissected. Therefore, nodal status is an important prognostic factor in predicting survival and systematic nodal dissection is mandatory to treat carcinoids with curative intent.
Concerning the type of resection, some authors believe wedge resection to be safe for small peripheral typical carcinoid tumors.[7] Fox et al.[11] stated that, compared to lobectomy, sublobar resection is not inferior in regarding survival in typical carcinoid patients. But there are reports that sublobar resections may be related with locoregional recurrence, and high probability of missing eventual N1 lymph nodes.[3,9] Aydin et al.[4] reported that overall survival was lowest in the wedge group. Therefore, we also recommend completion lobectomy when frozen section is tumor free but paraffin positive, in case of wedge resection cases. Carcinoid tumors are malignant neoplasms and should be treated with anatomical resection. Nonanatomic resection was not performed in our study. The latest publications also noted that parenchyma-sparing resections are suitable for proximal carcinoid tumors.[12]
In conclusion, we demonstrated that atypical presentation (p=0.005), and nodal invasion (p=0.008) were both negative prognostic factors. Prognosis does not seem to be related to sex (p=0.433), age (p=0.474), smoking history (p=0.726), comorbidity (p=0.062), central or peripheral localization (p=0.717), or T status (p=0.300). For optimal oncological results, an anatomic lung resection associated with systematic mediastinal lymphadenectomy is crucial.
Declaration of conflicting interests
The authors declared no conflicts of interest with respect to
the authorship and/or publication of this article.
Funding
The authors received no financial support for the research
and/or authorship of this article.
1) Naalsund A, Rostad H, Strøm EH, Lund MB, Strand
TE. Carcinoid lung tumors--incidence, treatment and
outcomes: a population-based study. Eur J Cardiothorac Surg 2011;39:565-9.
2) Travis WD, Brambilla E, Muller-Hermlink HK, Harris
CC. World Health Organization classification of tumors.
Pathology and genetics of tumours of the lung, pleura,
thymus and heart. Lyon: IARC Press; 2004.
3) Filosso PL, Oliaro A, Ruffini E, Bora G, Lyberis P, Asioli
S, et al. Outcome and prognostic factors in bronchial
carcinoids: a single-center experience. J Thorac Oncol
2013;8:1282-8.
4) Aydin E, Yazici U, Gulgosteren M, Agackiran Y, Kaya S,
Gulhan E, et al. Long-term outcomes and prognostic factors
of patients with surgically treated pulmonary carcinoid: our
institutional experience with 104 patients. Eur J Cardiothorac
Surg 2011;39:549-54.
5) Karapınar K, Saydam Ö, Büyükkale S, Metin M,
Günlüoğlu Z, Demir A, et al. Long-term results of surgical
treatment of pulmonary carcinoids. Turk Gogus Kalp
Dama 2015;23:304-8.
6) Filosso PL, Rena O, Donati G, Casadio C, Ruffini E,
Papalia E, et al. Bronchial carcinoid tumors: surgical
management and long-term outcome. J Thorac Cardiovasc
Surg 2002;123:303-9.
7) Ferguson MK, Landreneau RJ, Hazelrigg SR, Altorki
NK, Naunheim KS, Zwischenberger JB, et al. Long-term
outcome after resection for bronchial carcinoid tumors. Eur J
Cardiothorac Surg 2000;18:156-61.
8) Wurtz A, Benhamed L, Conti M, Bouchindhomme B,
Porte H. Results of systematic nodal dissection in typical
and atypical carcinoid tumors of the lung. J Thorac Oncol
2009;4:388-94.
9) Cañizares MA, Matilla JM, Cueto A, Algar J, Muguruza I,
Moreno-Mata N, et al. Atypical carcinoid tumours of the
lung: prognostic factors and patterns of recurrence. Thorax
2014;69:648-53.
10) García-Yuste M, Matilla JM, Cueto A, Paniagua JM, Ramos
G, Cañizares MA, et al. Typical and atypical carcinoid
tumours: analysis of the experience of the Spanish Multicentric
Study of Neuroendocrine Tumours of the Lung. Eur J
Cardiothorac Surg 2007;31:192-7.